Resolutions at Extraordinary General Meeting in Karo Pharma AB on July 21 2016
STOCKHOLM, Sweden, July 21, 2016 – At today’s Extraordinary General Meeting in Karo Pharma the following main resolutions were passed The meeting resolved in accordance with the board´s proposal for a resolution to issue stock options and to implement an option plan for personnelThe resolution concerns an issue of maximum 5,200,000 options. The right to subscribe for the options shall, with deviation from the shareholders´ preferential rights, be vested in Karo Pharma AB's wholly owned subsidiary Karo Pharma Research AB, reg. no. 556588-3641, (the "Subsidiary"), which will offer